Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

Background<br/> Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas. The current recommended treatment regimen for the radical cure of P. vivax includes a schizontocidal antimalarial, usually chloroquine, combined...

Full description

Bibliographic Details
Main Authors:	Abreha, T, Alemayehu, B, Assefa, A, Awab, G, Baird, J, Bezabih, B, Cheah, P, Day, N, Devine, A, Dorda, M, Dondorp, A, Girma, S, Hien, T, Jima, D, Kassa, M, Kebende, A, Khu, N, Leslie, T, Ley, B, Lubell, Y, Mayan, I, Meaku, Z, Pasaribu, A, Phu, N, Price, R, Simpson, J, Solomon, H, Sutanto, I, Tadesse, Y, Taylor, B, Thanh, N, Thriemer, K, von Seidlein, L, White, N, Woyessa, A, Yuentrakul, P, Zekria, R, Study Group, IMPROV
Format:	Journal article
Published:	BioMed Central 2015

Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

Similar Items